NCT06283589View on ClinicalTrials.gov

The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

July 27, 2024

Study Completion Date

December 13, 2024

Conditions
Calciphylaxis
Interventions
DRUG

INZ-701

Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Trial Locations (2)

33024

Elixia Health, Hollywood

33071

South Florida Nephrology Research, Coral Springs

Sponsors

Lead Sponsor

Inozyme Pharma
All Listed Sponsors
lead

Inozyme Pharma

INDUSTRY

NCT06283589 - The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis | Biotech Hunter | Biotech Hunter